• The new test enables clinicians to reliably diagnose HDV and monitor patients’ treatment response.
  • Hepatitis D  affects nearly 12 million of people globally and  is considered the most aggressive form of viral hepatitis, often leading to liver failure and cancer faster than other types.
  • The cobas HDV test is the first high-throughput, fully automated HDV assay on the market, addressing the urgent need for a consistent, widely accessible solution and expanding access to critical testing just as new treatments for the disease become available.